Novelos Therapeutics Announces Enrollment of First Patient in Lung Cancer … – MarketWatch (press release)
February 22, 2012
Novelos Therapeutics Announces Enrollment of First Patient in Lung Cancer ... MarketWatch (press release) "We look forward to obtaining initial LIGHT imaging data in the second quarter of 2012 in lung cancer patients. We believe positive data would establish proof-of-concept for LIGHT as a PET imaging agent for NSCLC, could advance our partnering ... and more » |
Related Articles
- Novelos Therapeutics Announces Successful Completion of First Cohort In Lung … – MarketWatch (press release)
- Novelos Therapeutics Announces Successful Completion of First Cohort In Lung …
- Novelos shelves failed lung cancer program – FierceBiotech
- ImmunoCellular Therapeutics Announces Year-End Results
- Novelos ends development of lung cancer drug – Mass High Tech
- Biomoda Completes Patient Enrollment and Sample Collection in Pilot Study
- Biomoda Completes Patient Enrollment and Sample Collection in Pilot Study – MarketWatch (press release)
- Allos Therapeutics Announces Topline Results from Phase 2b Study of FOLOTYN in … – MarketWatch (press release)
- Peregrine (PPHM) Completes Enrollment in Bavituximab Phase II – StreetInsider.com (subscription)
- OSI Pharmaceuticals Announces That “RADIANT”, an International Phase III …
Comments
¿Would you like to make a comments?